As of November 6, 2026, 9 holders' latest Schedule 13D or 13G filings report owning 5% or more of PAVmed Inc. The largest reported stake is Dana Carrera's, at 15.3%. 14 filings are on record since August 14, 2025 (Schedule 13G/A, April 14, 2026).
Sell to companies like PAVmed Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Dols Scott V. · Sole voting: 463,155 · Shared voting: 0 · Sole dispositive: 463,155 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-11-03
- · Reporting person: Kallman Craig · Sole voting: 399,752 · Shared voting: 0 · Sole dispositive: 399,752 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-10-23
- · Reporting person: Nagelberg David S · Sole voting: 699,778 · Shared voting: 0 · Sole dispositive: 699,778 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-13
- · Holder: Two Seas Capital LP · Percent: 9.99% · SCHEDULE 13G
- · Holder: First Manhattan Co. LLC. · Percent: 9.6% · SCHEDULE 13G
PAVmed Inc. has 14 Schedule 13D or 13G filings on record since 2025-08-14. 9 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 15.3% | 974,246 | SCHEDULE 13G/A, 2026-04-14 | 2026-03-27 | |
| Ayrton Capital LLC | 9.99% | 709,069 | SCHEDULE 13G/A, 2026-05-11 | 2026-03-31 |
| Two Seas Capital LP | 9.99% | 657,219 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
| Scopia Holdings LLC | 9.9% | 630,118 | SCHEDULE 13G, 2026-04-13 | 2026-03-27 |
| First Manhattan Co. LLC. | 9.6% | 639,191 | SCHEDULE 13G, 2026-05-14 | 2026-03-31 |
| 8.8% | 699,778 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 | |
| Sargent Investment Group, LLC | 5.8% | 1,006,300 | SCHEDULE 13G, 2025-08-14 | 2025-07-01 |
| 5.8% | 463,155 | SCHEDULE 13G/A, 2026-11-03 | 2026-09-30 | |
| 5.1% | 369,068 | SCHEDULE 13D, 2026-04-09 | 2026-04-02 | |
| 4.9% | 399,752 | SCHEDULE 13G/A, 2026-10-23 | 2026-09-30 |
Holding shares or following this stake? See who's behind PAVmed Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on PAVmed Inc. and the records around it.
The people at PAVmed Inc.
- Dennis McGrath is also named on 10 other Form D filings: DarioHealth Corp. (Oct 2025), Veris Health Inc. (Jul 2025)
- Lishan Aklog is also named on 4 other Form D filings: Veris Health Inc. (Jul 2025)
- Timothy Baxter is also named on 2 other Form D filings: Veris Health Inc. (Jul 2025)
PAVmed Inc. elsewhere on the record
- Company profile and every filing Feb 2026
- Form D filing Feb 2026
- Who owns it
Companies that share a holder
- Kallman Craig also filed stake reports on 1 other company: DarioHealth Corp. (Dec 2025)
- Tasso Partners, LLC also filed stake reports on 2 other companies: Orchestra BioMed Holdings, Inc. (Nov 2025), DarioHealth Corp. (Nov 2025)
- FIRST MANHATTAN CO. LLC. also filed stake reports on 4 other companies: EagleRock Land, LLC (Nov 2026), Bridger Aerospace Group Holdings, Inc. (Apr 2026), NN INC (Nov 2025)
Watch PAVmed Inc.
Get an email when PAVmed Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on PAVmed Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on PAVmed Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on PAVmed Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Nagelberg David S | 699,778 | 0 | 699,778 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| David S. Nagelberg 2003 Revocable Trust Dtd. 07/02/03 | 474,542 | 0 | 474,542 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Dols Scott V. | 463,155 | 0 | 463,155 | 0 | SCHEDULE 13G/A, 2026-11-03 |
| Kallman Craig | 399,752 | 0 | 399,752 | 0 | SCHEDULE 13G/A, 2026-10-23 |
| Craig Kallman 2015 Living Trust | 399,752 | 0 | 399,752 | 0 | SCHEDULE 13G/A, 2026-10-23 |
The latest filing identifies PAVmed Inc. by CUSIP 70387R502 and gives its principal executive office as 360 MADISON AVENUE, 25TH FLOOR, NEW YORK, NY 10017 (SCHEDULE 13G/A, 2026-11-03).
What the percentages are based on
As of August 13, 2026, the Trust beneficially owns 5.9% of the outstanding shares of Common Stock. As of August 13, 2026, Mr. Nagelberg beneficially owns 8.8% of the outstanding shares of Common Stock. The percentage of beneficial ownership is calculated based on 7,995,918 shares of Common Stock outstanding as of August 13, 2026, as set forth in the Company's quarterly report on Form 10-Q filed on August 13, 2026.Nagelberg David S, SCHEDULE 13G/A, 2026-08-13
Mr. Dols beneficially owns 5.8% of the outstanding shares of Common Stock. The percentage of beneficial ownership is calculated based on 7,995,918 shares of Common Stock outstanding as of August 13, 2026, as set forth in the Company's quarterly report on Form 10-Q filed on August 13, 2026.Dols Scott V., SCHEDULE 13G/A, 2026-11-03
Each of the Trust and Mr. Kallman beneficially owns 4.9% of the outstanding shares of Common Stock. The percentage of beneficial ownership is calculated based on 7,995,918 shares of Common Stock outstanding as of August 13, 2026, as set forth in the Company's quarterly report on Form 10-Q filed on August 13, 2026.Kallman Craig, SCHEDULE 13G/A, 2026-10-23
Purpose of Transaction (Item 4)
Aklog Lishan
Dr. Aklog acquired beneficial ownership of the shares of Common Stock described in this Schedule 13D for investment purposes. Dr. Aklog may from time to time acquire beneficial ownership of additional securities for investment purposes, or dispose of securities, in the open market or in private transactions, including upon exercise of options described below and subject to the restricted stock agreements described below. At the date of this Schedule 13D, except as set forth in this Schedule 13D, and as consistent with Dr. Aklog's position as Chairman and Chief Executive Officer of the Issuer, Dr. Aklog has no plans or proposals which would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of the board of directors or management of the Issuer; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure; (g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may …The first part of Item 4 of the SCHEDULE 13D filed 2026-04-09; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Sargent Investment Group, LLC | 5.8% | SCHEDULE 13G |
| 2026-04-03 | Tasso Partners, LLC | 14.3% | SCHEDULE 13G/A |
| 2026-04-03 | Kallman Craig | 6% | SCHEDULE 13G |
| 2026-04-08 | Dols Scott V. | 5.4% | SCHEDULE 13G |
| 2026-04-08 | Nagelberg David S | 8.6% | SCHEDULE 13G |
| 2026-04-09 | Aklog Lishan | 5.1% | SCHEDULE 13D |
| 2026-04-13 | Scopia Holdings LLC | 9.9% | SCHEDULE 13G |
| 2026-04-14 | Dana Carrera | 15.3% | SCHEDULE 13G/A |
| 2026-05-11 | Ayrton Capital LLC | 9.99% | SCHEDULE 13G/A |
| 2026-05-14 | First Manhattan Co. LLC. | 9.6% | SCHEDULE 13G |
| 2026-05-15 | Two Seas Capital LP | 9.99% | SCHEDULE 13G |
| 2026-08-13 | Nagelberg David S | 8.8% | SCHEDULE 13G/A |
| 2026-10-23 | Kallman Craig | 4.9% | SCHEDULE 13G/A |
| 2026-11-03 | Dols Scott V. | 5.8% | SCHEDULE 13G/A |
Questions about who owns PAVmed Inc.
Who owns PAVmed Inc.?
On this page, 9 holders' latest ownership filings report 5% or more of PAVmed Inc.: Dana Carrera (15.3%, Schedule 13G/A, filed 2026-04-14), Ayrton Capital LLC (9.99%, Schedule 13G/A, filed 2026-05-11), Two Seas Capital LP (9.99%, Schedule 13G, filed 2026-05-15), Scopia Holdings LLC (9.9%, Schedule 13G, filed 2026-04-13) and First Manhattan Co. LLC. (9.6%, Schedule 13G, filed 2026-05-14); 4 more are listed above.
Who are the largest shareholders of PAVmed Inc.?
By the share each holder's latest filing reports, the largest holders of PAVmed Inc. on this page are Dana Carrera (15.3%), Ayrton Capital LLC (9.99%) and Two Seas Capital LP (9.99%).
When did Dana Carrera buy into PAVmed Inc.?
The filings give report dates, not purchase dates. The earliest filing from Dana Carrera on this page is the Schedule 13G/A, filed 2026-04-14, reporting 15.3%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 14 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for PAVmed Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| February 17, 2026 | Form D, private offering | $30M sold | Form D page | Source |
| February 7, 2025 | Form D, private offering | $2.65M sold | Form D page | Source |
| December 23, 2020 | Court case: Benchmark Investments, Inc. v. PAVmed Inc., District Court, S.D. New York | — | Court records | Source |
PAVmed Inc.: every filing and event
Tools for this story
Each opens in a new tab, filled in for PAVmed Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.